138 related articles for article (PubMed ID: 35648430)
21. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
22. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain.
Galan-Gutierrez M; Font-Ugalde P; Padilla L; Hernandez-Montoya C; Godoy D; Armario-Hita JC; Ruiz-Villaverde R
Int J Dermatol; 2023 May; 62(5):700-706. PubMed ID: 36495585
[TBL] [Abstract][Full Text] [Related]
23. Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis.
Yamaguchi Y; Kanai Y; Kitabayashi H; Okada H; Nakagawa H
J Dermatol; 2021 Mar; 48(3):324-333. PubMed ID: 33161605
[TBL] [Abstract][Full Text] [Related]
24. Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks.
Rompoti N; Politou M; Stefanaki I; Vavouli C; Papoutsaki M; Neofotistou A; Rigopoulos D; Stratigos A; Nicolaidou E
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):689-697. PubMed ID: 36562663
[TBL] [Abstract][Full Text] [Related]
25. Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study.
Yamaguchi Y; Takatsu N; Ootaki K; Nakagawa H
J Dermatol; 2020 Jun; 47(6):569-577. PubMed ID: 32275086
[TBL] [Abstract][Full Text] [Related]
26. Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study.
Rigopoulos D; Angelakopoulos C; Apalla Z; Georgiou S; Delli F; Drosos A; Zafiriou E; Katsantonis J; Lazaridou E; Panagakis P; Papadavid E; Papakonstantis M; Roussaki-Schulze AV; Sotiriou E; Anastasiadis G; Tampouratzi E; Chasapi V; Sfaelos K; Ioannides D;
Dermatol Ther; 2022 Dec; 35(12):e15886. PubMed ID: 36184757
[TBL] [Abstract][Full Text] [Related]
27. Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece.
Papadavid E; Zafeiriou E; Georgiou S; Roussaki-Schulze AV; Spiliopoulos T; Vryzaki E; Oikonomou C; Drongoula O; Boziou M; Goudouras G; Sfaelos K; Apalla Z; Lazaridou E
J Dermatolog Treat; 2022 Nov; 33(7):3053-3059. PubMed ID: 36000186
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
McMichael A; Desai SR; Qureshi A; Rastogi S; Alexis AF
Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
[TBL] [Abstract][Full Text] [Related]
29. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.
Megna M; Potestio L; Camela E; Fabbrocini G; Ruggiero A
Dermatol Ther; 2022 Sep; 35(9):e15667. PubMed ID: 35762107
[TBL] [Abstract][Full Text] [Related]
30. Treatment with brodalumab is not associated with improved sleep problems in real-life patients with plaque psoriasis: Results of the ProLOGUE study.
Mizutani Y; Kanai Y; Murotani K; Honma M; Higashiyama M; Kobayashi S; Nomura T; Seishima M; Imafuku S
J Dermatol; 2023 Mar; 50(3):319-326. PubMed ID: 36342070
[TBL] [Abstract][Full Text] [Related]
31. Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch.
Gaudet V; Yap B; Hassan S; Barbeau M
J Cutan Med Surg; 2023; 27(3):226-235. PubMed ID: 37083148
[TBL] [Abstract][Full Text] [Related]
32. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
[TBL] [Abstract][Full Text] [Related]
34. Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: Experience from clinical practice of four tertiary hospitals.
Tampouratzi E; Papakonstantis M; Katsantonis J; Sidiropoulos T; Delli F; Efthymiadis K; Sfaelos K; Christodoulou A; Chasapi V; Panagakis P
Dermatol Ther; 2022 Jul; 35(7):e15532. PubMed ID: 35451147
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
[TBL] [Abstract][Full Text] [Related]
36. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
Puig L
Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of brodalumab in improving itching and skin pain in Japanese patients with psoriasis: The ProLOGUE study.
Honma M; Kanai Y; Murotani K; Ito K; Ohata C; Yamazaki F; Saeki H; Seishima M; Mizutani Y; Kitabayashi H; Imafuku S
J Dermatol; 2023 Apr; 50(4):453-461. PubMed ID: 36540010
[TBL] [Abstract][Full Text] [Related]
38. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
39. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
[TBL] [Abstract][Full Text] [Related]
40. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis.
Umezawa Y; Nakagawa H; Niiro H; Ootaki K;
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1957-1960. PubMed ID: 27358210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
